Digestive Diseases and Sciences

, Volume 54, Issue 9, pp 1829–1834 | Cite as

Gastroesophageal Reflux Disease (GERD) and Irritable Bowel Syndrome (IBS)—Is It One Disease or an Overlap of Two Disorders?

  • Anita Gasiorowska
  • Choo Hean Poh
  • Ronnie FassEmail author


Up to 79% of IBS patients report gastroesophageal reflux disease (GERD) symptoms, and up to 71% of GERD patients report irritable bowel syndrome (IBS) symptoms. There are two principal hypotheses for the common presence of IBS symptoms in GERD patients. The first theory suggests that GERD and IBS overlap in a significant number of patients. The second theory suggests that IBS-like symptoms are part of the spectrum of GERD manifestation. The first theory is supported by genetic studies and similarities in gastrointestinal sensory-motor abnormalities potentially due to general gastrointestinal disorder of smooth muscle or sensory afferents. The other theory is primarily supported by studies demonstrating improvement of IBS-like symptoms in GERD patients receiving anti-reflux treatment. The close relationship between GERD and IBS could be explained by either GERD affecting different levels of the GI tract or a high overlap rate between GERD and IBS due to similar underlying GI dysfunction.


Gastroesophageal reflux disease (GERD) Irritable bowel syndrome (IBS) Pathophysiologic mechanism Symptom assessment Visceral hyperalgesia 



The authors wish to acknowledge the grant support from AstraZeneca, Eisai, TAP, and Vecta.


  1. 1.
    Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–1915.PubMedGoogle Scholar
  2. 2.
    Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut. 1998;42:690–695.PubMedGoogle Scholar
  3. 3.
    Spiller R, Aziz Q, Creed F, et al. Clinical services committee of the British society of gastroenterology: guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770–1798. doi: 10.1136/gut.2007.119446.PubMedCrossRefGoogle Scholar
  4. 4.
    Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology. 1987;92:1282–1284.PubMedGoogle Scholar
  5. 5.
    Fullard M, Kang JY, Neild P, Poullis A, Maxwell JD. Systematic review: does gastro-oesophageal reflux disease progress? Aliment Pharmacol Ther. 2006;24:33–45. doi: 10.1111/j.1365-2036.2006.02963.x.PubMedCrossRefGoogle Scholar
  6. 6.
    Cheung TK, Lam KF, Hu WH, et al. Positive association between gastro-oesophageal reflux disease and irritable bowel syndrome in a Chinese population. Aliment Pharmacol Ther. 2007;25:1099–1104.PubMedGoogle Scholar
  7. 7.
    Hu WH, Wong WM, Lam CL, et al. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther. 2002;16:2081–2088. doi: 10.1046/j.1365-2036.2002.01377.x.
  8. 8.
    Talley NJ, Dennis EH, Schettler-Duncan V, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol. 2003;98:2454–2459. doi: 10.1111/j.1572-0241.2003.07699.x.PubMedCrossRefGoogle Scholar
  9. 9.
    Zimmerman B, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol. 2008;42:261–265.PubMedGoogle Scholar
  10. 10.
    Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96:2905–2914.PubMedGoogle Scholar
  11. 11.
    Locke GR 3rd, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil. 2005;17:29–34. doi: 10.1111/j.1365-2982.2004.00581.x.PubMedCrossRefGoogle Scholar
  12. 12.
    Pimentel M, Rossi F, Chow EJ, et al. Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux. J Clin Gastroenterol. 2002;34:221–224. doi: 10.1097/00004836-200203000-00004.PubMedCrossRefGoogle Scholar
  13. 13.
    Wong WM, Fass R. Extraesophageal and atypical manifestations of GERD. J Gastroenterol Hepatol. 2004;19:S33–S43. doi: 10.1111/j.1440-1746.2004.03589.x.PubMedCrossRefGoogle Scholar
  14. 14.
    Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21:1365–1375. doi: 10.1111/j.1365-2036.2005.02463.x.PubMedCrossRefGoogle Scholar
  15. 15.
    Zimmerman J. Extraintestinal symptoms in irritable bowel syndrome and inflammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms. Dig Dis Sci. 2003;48:743–749. doi: 10.1023/A:1022840910283.PubMedCrossRefGoogle Scholar
  16. 16.
    Kennedy TM, Jones RH, Hungin AP, O’Flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770–774.PubMedGoogle Scholar
  17. 17.
    De Vries DR, Van Herwaarden MA, Baron A, Smout AJ, Samsom M. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease. Scand J Gastroenterol. 2007;42:951–956. doi: 10.1080/00365520701204204.PubMedCrossRefGoogle Scholar
  18. 18.
    Zimmerman J. Irritable bowel, smoking and oesophageal acid exposure: an insight into the nature of symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2004;20:1297–1303. doi: 10.1111/j.1365-2036.2004.02216.x.PubMedCrossRefGoogle Scholar
  19. 19.
    Fass R, Stanghellini V, Monnikes H. Baseline analysis of symptom spectrum in GERD clinical trial patients: result from ReQuest database. Gastroenterology. 2006;130:A629.Google Scholar
  20. 20.
    Guillemot F, Ducrotte P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol. 2005;29:243–246. doi: 10.1016/S0399-8320(05)80756-0.PubMedGoogle Scholar
  21. 21.
    Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci. 2006;51:2113–2120. doi: 10.1007/s10620-006-9306-y.PubMedCrossRefGoogle Scholar
  22. 22.
    Smart HL, Nicholson DA, Atkinson M. Gastro-oesophageal reflux in the irritable bowel syndrome. Gut. 1986;27:1127–1131. doi: 10.1136/gut.27.10.1127.PubMedCrossRefGoogle Scholar
  23. 23.
    Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut. 1986;27:37–40. doi: 10.1136/gut.27.1.37.PubMedCrossRefGoogle Scholar
  24. 24.
    Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006;6:72–78.PubMedGoogle Scholar
  25. 25.
    Talley NJ. Overlapping abdominal symptoms: why do GERD and IBS often coexist? Drugs Today (Barc). 2006;42:3–8. doi: 10.1358/dot.2006.42.1.893611.CrossRefGoogle Scholar
  26. 26.
    Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther. 2007;25:1343–1350.PubMedGoogle Scholar
  27. 27.
    Dickman R, Feroze H, Fass R. Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep. 2006;8:261–265. doi: 10.1007/s11894-006-0045-1.PubMedCrossRefGoogle Scholar
  28. 28.
    Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304:87–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Costantini M, Sturniolo GC, Zaninotto G, et al. Altered esophageal pain threshold in irritable bowel syndrome. Dig Dis Sci. 1993;38:206–212. doi: 10.1007/BF01307536.PubMedCrossRefGoogle Scholar
  30. 30.
    Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–453.PubMedGoogle Scholar
  31. 31.
    Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995;40:1607–1613. doi: 10.1007/BF02212678.PubMedCrossRefGoogle Scholar
  32. 32.
    Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol. 2008;6:393–400. doi: 10.1016/j.cgh.2008.02.016.PubMedCrossRefGoogle Scholar
  33. 33.
    Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs. 2007;67:1521–1530. doi: 10.2165/00003495-200767110-00001.PubMedCrossRefGoogle Scholar
  34. 34.
    Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther. 2007;26:453–461.PubMedCrossRefGoogle Scholar
  35. 35.
    Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:473–482.PubMedCrossRefGoogle Scholar
  36. 36.
    Raftopoulos Y, Papasavas P, Landreneau R, et al. Clinical outcome of laparoscopic antireflux surgery for patients with irritable bowel syndrome. Surg Endosc. 2004;18:655–659. doi: 10.1007/s00464-003-8162-5.PubMedCrossRefGoogle Scholar
  37. 37.
    Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49:193–197.PubMedGoogle Scholar
  38. 38.
    Stanghellini V, Armstrong D, Mönnikes H, Berghöfer P, Gatz G, Bardhan KD. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion. 2007;75:55–61. doi: 10.1159/000101083.PubMedCrossRefGoogle Scholar
  39. 39.
    Glatzel D, Abdel-Quader M, Gatz G, Pfaffenberger B. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007;75:69–78. doi: 10.1159/000101085.PubMedCrossRefGoogle Scholar
  40. 40.
    Monnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2007;75:62–68.PubMedGoogle Scholar
  41. 41.
    Stanghellini V. ReQuest: new dimensions in the assessment and management of GERD. Drugs Today (Barc). 2005;41:7–11.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Anita Gasiorowska
    • 1
  • Choo Hean Poh
    • 1
  • Ronnie Fass
    • 1
    Email author
  1. 1.Neuroenteric Clinical Research Group, Southern Arizona VA Health Care SystemUniversity of ArizonaTucsonUSA

Personalised recommendations